BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 29
• 30

• 

  Duchenne muscular dystrophy

  Dyne’s Exon Skipper Delivers ‘Best Ever’ Functional Outcomes in Early DMD Study

  Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for this treatment class, Stifel analysts said.

  December 8, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  ASH25: CAR-T Leaders Gilead, J&J Show in Multiple Myeloma; Fulcrum Rises on Sickle Cell Data

  The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare diseases.

  December 8, 2025

   · 

  5 min read

   · 

  Tristan Manalac
• Press Releases

  Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

  December 8, 2025

   · 

  5 min read
• Press Releases

  CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium

  December 8, 2025

   · 

  5 min read
• Press Releases

  Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

  December 8, 2025

   · 

  10 min read
• Press Releases

  Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

  December 8, 2025

   · 

  21 min read
• 

  Weight loss

  Wave Soars on Early Results for Obesity Treatment That Could ‘Disrupt’ the Landscape

  Although still in Phase I, Wave Life Sciences’ injectable RNA weight loss treatment achieved results that impressed analysts, with 4% fat reduction after three months, beating Novo Nordisk’s semaglutide at a similar time point.

  December 8, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Insights

  As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation

  The agency’s sweeping rollout and staff challenge underscore rising momentum behind agentic AI: advanced, multiagent systems now fueling early pilots in medical writing, patient engagement and regulatory workflows across the industry.

  December 8, 2025

   · 

  3 min read

   · 

  Jennifer C. Smith-Parker